Login / Signup

Prognostic tools and candidate drugs based on plasma proteomics of patients with severe COVID-19 complications.

Maryam A Y Al-NesfHouari B AbdesselemIlham BensmailShahd I IbrahimWalaa A H SaeedSara S I MohammedAlmurtada RazokHashim AlhussainReham M A AlyMuna Al MaslamaniKhalid OuararhniMohamad Y KhatibAli Ait HssainAli S OmraniSaad Al-KaabiAbdullatif Al KhalAsmaa A Al-ThaniWaseem SamsamAbdulaziz FarooqJassim Al-SuwaidiMohammed Al MaadheedHeba H Al-SiddiqiAlexandra E ButlerJulie V DecockVidya Mohamed-AliFares Al-Ejeh
Published in: Nature communications (2022)
COVID-19 complications still present a huge burden on healthcare systems and warrant predictive risk models to triage patients and inform early intervention. Here, we profile 893 plasma proteins from 50 severe and 50 mild-moderate COVID-19 patients, and 50 healthy controls, and show that 375 proteins are differentially expressed in the plasma of severe COVID-19 patients. These differentially expressed plasma proteins are implicated in the pathogenesis of COVID-19 and present targets for candidate drugs to prevent or treat severe complications. Based on the plasma proteomics and clinical lab tests, we also report a 12-plasma protein signature and a model of seven routine clinical tests that validate in an independent cohort as early risk predictors of COVID-19 severity and patient survival. The risk predictors and candidate drugs described in our study can be used and developed for personalized management of SARS-CoV-2 infected patients.
Keyphrases